Page 116 - Binder2

This specificity is what makes Tregs so powerful in the
context of biologics.

The result?
A biologic that the immune system learns to ignore, but
without compromising its ability to respond to pathogens or
tumors.

That’s the holy grail: targeted tolerance.

And yet, most biologic drug designs do nothing to engage
this pathway. They don’t stimulate Tregs. They don’t
mimic the context in which Tregs are induced. In fact, by
delivering drugs in ways the immune system interprets as
danger signals, they often suppress Treg development
entirely, or even provoke the exact effector T cells that
neutralize the therapy.

This is not inevitable.
It’s avoidable—if we build biologics that cooperate with
Tregs instead of ignoring them.

Because in the long arc of immune memory, a Treg is far
more powerful than any suppressive co-therapy.
It’s not a Band-Aid. It’s a rewiring of perception.

And if biologics are ever going to become durable
therapies—measured in years, not quarters—then Tregs
aren’t optional. They’re essential.

This isn’t just a quirk of gut biology. It’s an evolutionary
adaptation. A way to prevent the immune system from
overreacting to food, commensals, and self.

And it’s exactly the pathway we should be engaging when
introducing complex biologics.

114